
1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole NEW
Price | Get Latest Price | |
Package | 1kg | 25kg |
Min. Order: | 1kg |
Supply Ability: | 800kg |
Update Time: | 2025-04-01 |
Product Details
Product Name: 1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole | CAS No.: 1029716-44-6 |
Min. Order: 1kg | Purity: 0.99 |
Supply Ability: 800kg | Release date: 2025/04/01 |
?Baricitinib Intermediate (CAS 1029716-44-6)?
Google Keywords: Baricitinib Intermediate, CAS 1029716-44-6, JAK Inhibitor Synthesis, Rheumatoid Arthritis API Intermediates, GMP Pharmaceutical Manufacturing
?? ?Product Overview?
?Baricitinib Intermediate? (CAS 1029716-44-6) is a high-purity chemical intermediate essential for synthesizing ?Baricitinib?, a Janus kinase (JAK) inhibitor approved for treating rheumatoid arthritis and severe inflammatory conditions. This intermediate ensures precision and scalability in API production while adhering to stringent pharmaceutical quality standards.
?Primary Function?: Acts as a critical building block in the multi-step synthesis of Baricitinib API.
?Applications?: Rheumatoid arthritis drug development, JAK inhibitor manufacturing, and large-scale API production.
? ?Key Advantages?
?? ?Ultra-High Purity? | ≥99.0% (HPLC/GC verified) | Complies with ICH Q11 guidelines for intermediates.
?? ?Scalable Synthesis? | Optimized for high-yield, cost-effective manufacturing with minimal impurities.
?? ?Regulatory Compliance? | Fully characterized by NMR, HRMS, and FTIR to support FDA/EMA submissions and GMP audits.
?? ?Applications?
?API Production?: Enables efficient synthesis of Baricitinib with consistent quality.
?Process Optimization?: Supports R&D in refining synthetic pathways for improved efficiency.
?Quality Control?: Used in analytical method validation and batch release testing.
?? ?Quality Assurance?
?Testing Methods?: HPLC, GC, NMR, HRMS, and FTIR for structural confirmation and purity analysis.
?Standards?: Meets USP <1086>, EP 10.0, and ISO 9001:2015 certified manufacturing protocols.
?? ?Market Trends?
The ?global rheumatoid arthritis treatment market? is projected to exceed ?$38.5 billion by 2030? (CAGR 5.8%), driven by rising autoimmune disease prevalence and demand for targeted therapies like JAK inhibitors. Baricitinib intermediates are pivotal in accelerating generic and innovative drug development post-patent expiry.
Enhance your JAK inhibitor production with Baricitinib Intermediate – precision-engineered for quality, scalability, and regulatory excellence.
Company Profile Introduction
You may like
-
CAS:545445-44-1
$0.00 / 1kg
-
CAS:1029716-44-6
$0.00 / 1kg
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/1kg |
VIP1Y
|
Hebei Junhua Import and Export Co., LTD
|
2025-04-01 | |
$0.00/25KG |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-02-17 | |
$5.00/1KG |
VIP2Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-10 | |
$0.00/1kg |
Nanjing Fred Technology Co., Ltd
|
2023-12-29 | ||
$0.00/1kg |
VIP2Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-07-03 | |
$0.00/1KG |
VIP3Y
|
Henan Aochuang Chemical Co.,Ltd.
|
2022-10-08 | |
$300.00/1kg |
Hebei Mingeng Biotechnology Co., Ltd
|
2022-05-05 | ||
$15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
$850.00/1Kg/Bag |
Pharmahands (Taizhou) Co., Ltd.
|
2020-09-15 | ||
$1.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-20 |
+86-+undefined-+86 13343427080
sales@biocarchem.com